FMP
Satsuma Pharmaceuticals, Inc.
STSA
NASDAQ
Inactive Equity
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
1.1 USD
0 (0%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. John A. Kollins MBA
sector
Healthcare
industry
Biotechnology
website
https://www.satsumarx.comexchange
NASDAQ
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
CIK
0001692830
ISIN
US80405P1075
CUSIP
80405P107
Address
400 Oyster Point Boulevard
Phone
650 410 3200
Country
US
Employee
25
IPO Date
Sep 13, 2019
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
STSA Financial Summary
CIK
0001692830
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
80405P107
ISIN
US80405P1075
Country
US
Price
1.1
Beta
0.1
Volume Avg.
1.11M
Market Cap
36.47M
Shares
-
52-Week
0.59-8.08
DCF
4.52
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.55
P/B
-
Website
https://www.satsumarx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest STSA News
It looks like there's no news available.
